UK ranks 22nd out of 29 comparable countries for survival of Brain Cancer
NW Biotherapeutics, maker of DC Vax to treat glioblastoma — applied for approval in the UK.
NW Biotherapeutics, maker of DC Vax to treat glioblastoma — applied for approval in the UK.
NW Biotherapeutics, maker of DC Vax to treat glioblastoma — applied for approval in the UK.
OurBrainBank is proud that the White House invited us to be part of the ambitious Cancer Moonshot effort. Read the latest from Washington DC.
Executive Director Kelli Duprey presented our poster about treatment disparities at SNO 2023
Clinical trial for people newly diagnosed with glioblastoma
Model could help doctors identify patients with cellular characteristics that indicate more aggressive tumors, and flag them for accelerated follow-up.
Reading books about glioblastoma and other brain tumors can help.
Founder Jessica Morris’s family is running the Brighton marathon to raise funds for OurBrainBank!
This week, we presented preliminary results of our ambitious survey of 500+ people affected by GBM at the Society for Neuro-Oncology annual conference.
A good time was had by all at a festive evening of fun, live music, great food and drinks — all to benefit OurBrainBank. Let us know if you’d like to host a benefit event for us.
OurBrainBank is at the AONN+ (Academy of Oncology Nurse & Patient Navigators) annual conference in Las Vegas. Stop by our booth and poster to meet Executive Director Kelli Duprey and learn about our survey of disparities in GBM treatment across the USA.
